

Ref: FOI/GS/ID 9250

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

25 July 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Colorectal Cancer [CRC].

You asked: All questions are shown as received by the Trust.

In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens?

Can you please provide the total number of patients treated for CRC with each product and the total number of Metastatic patients treated with each product for CRC in the table below.

Aflibercept plus chemotherapy

Bevacizumab plus fluoropyrimidine-based chemotherapy

Capecitabine

CAPIRI

CAPOX

Cetuximab with FOLFIRI

Cetuximab with FOLFOX

Cetuximab as a single agent

Cetuximab with Encorafenib

Irinotecan as a single agent

FOLFIRI

FOLFOX

Fluorouracil (5FU) as a single agent

Oxaliplatin as a single agent

Nivolumab with Ipilimumab

Panitumumab with FOLFIRI

Panitumumab with FOLFOX

Panitumumab as a single agent

Pembrolizumab

Any other systemic anti-cancer therapy

Palliative care only

Trust response:

The below figures relate to patients treated at the Trust for a colorectal cancer between 01/04/24-30/06/24.

Regimens	Total CRC Patients	Metastatic CRC Patients
Aflibercept plus chemotherapy	0	0
Bevacizumab plus fluoropyrimidine-based chemotherapy	2	0
Capecitabine	31	14
CAPIRI	0	0
CAPOX	0	0
Cetuximab with FOLFIRI	18	7
Cetuximab with FOLFOX	0	0
Cetuximab as a single agent	1	1
Cetuximab with Encorafenib	1	0
Irinotecan as a single agent	0	0
FOLFIRI	60	29
FOLFOX	0	0
Fluorouracil (5FU) as a single agent	1	1
Oxaliplatin as a single agent	0	0
Nivolumab with Ipilimumab	0	0
Panitumumab with FOLFIRI	2	2
Panitumumab with FOLFOX	0	0
Panitumumab as a single agent	0	0
Pembrolizumab	8	2
Any other systemic anti-cancer therapy	44	20
Palliative care only	7	4